Description
The NLDC-145 monoclonal antibody specifically recognizes CD205 which is also known as Dendritic and thymic Epithelial Cells, 205 kDa (DEC-205) or Lymphocyte antigen 75 (Ly-75). CD205 (DEC-205) is a ~205 kDa type 1 transmembrane glycoprotein that is encoded by Ly75 which belongs to the mannose receptor family within the C-type lectin superfamily. The extracellular region contains an N-terminal cysteine-rich domain followed by a fibronectin type II domain, 10 C-type lectin-like domains, a transmembrane region and cytoplasmic tail with an internalization sequence. CD205 (DEC-205) is highly expressed on both CD8+ and CD103+ dendritic cell subsets and Langerhans cells. It is variably expressed by some other dendritic cell types, Gr1+ bone marrow cells, B cells, T cells, thioglycolate-elicited macrophages, granulocytes, mucosal and thymic cortical epithelial cells, and brain endothelial cells. CD205 (DEC-205) serves as a pattern recognition receptor that functions as a recycling endocytic receptor. It participates in the cellular processing, presentation, and cross-presentation of foreign or self-antigens to initiate immunity or tolerance, respectively. CD205 (DEC-205) can reportedly serve as a promising target for immunotherapy including DC-targeted vaccination using anti-CD205 (DEC-205) monoclonal antibody conjugated with antigen for T cell activation.
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
3. For U.S. patents that may apply, see bd.com/patents.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
6. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
7. Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
8. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
9. An isotype control should be used at the same concentration as the antibody of interest.
10. When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
11. CF™ is a trademark of Biotium, Inc.
12. Tandem fluorochromes contain both an energy donor and an energy acceptor. Although every effort is made to minimize the lot-to-lot variation in the efficiency of the fluorochrome energy transfer, differences in the residual emission from the donor may be observed. Additionally, multi-laser cytometers may directly excite both the donor and acceptor fluorochromes. Therefore, we recommend for every tandem conjugate, a matched individual single-stain control be acquired for generating a compensation or spectral unmixing matrix.
